JD Health (06618) reported a total revenue of RMB 40.9 billion for the first half of 2026, marking a 15.9% year-on-year increase. Under the Non-IFRS metric, its operating profit reached RMB 3.5 billion, up 40.3% from the same period last year.

The company focuses on its supply chain as a core strength, driving synergies between its self-operated, third-party platform, and instant retail businesses. It continues to expand its professional product offerings and reinforce its self-operated advantages, while also building an open ecosystem to grow alongside brand partners and platform merchants.

During the reporting period, JD Health further solidified its leadership in the pharmaceutical supply chain by launching 65 new drugs, covering areas such as chronic metabolic diseases, dermatology, and oncology. This reinforces its position as the "first stop for new drug launches nationwide." Additionally, by integrating specialized medical services with its self-operated drug supply chain, the company has established a differentiated edge in fields like dermatology and introduced AI-powered diagnostic tools built on the "Jingyi Qianxun" large model.

Online medical insurance payments have now been implemented in 40 cities, with JD Health pharmacies operating over 450 locations across 10 cities, achieving improvements in both supply fulfillment and service quality. From new drug launches to precise services, JD Health is leveraging its pharmaceutical supply chain as a foundation to continuously strengthen its full-cycle health service system.